麦角新碱联合缩宫素治疗宫缩乏力性产后出血的临床效果

Objective To investigate the clinical effect of ergometrine combined with oxytocin in the treatment of uterine atony-induced postpartum hemorrhage. Methods From January 2022 to June 2025, according to the inclusion and exclusion criteria, 120 patients with uterine atony-induced postpartum hemorrhage were selected as the research subjects, and were divided into a control group(n=60) and an observation group(n=60) according to the random number table method. The control group was treated with oxytocin, while the observation group was treated with methylergometrine in addition to the above treatment. The blood loss at different postpartum time points, the coagulation function before and after treatment, the stress response indicators, and the incidence of adverse reactions were compared between the two groups of patients. Results Compared with the control group, the blood loss of the observation group at 1h, 2h, 12h, and 24h after delivery was at a lower level(P<0.05). Compared with the control group, the thrombin time(TT), prothrombin time(PT), activated partial thromboplastin time(APTT) after treatment in the observation group were shorter, and the fibrinogen(FIB) level was higher(P<0.05). Compared with the control group, the angiotensin II(ANG II), aldosterone(ALD), epinephrine(E), and norepinephrine(NE) after treatment in the observation group were at lower levels(P<0.05). There was no significant difference in the incidence of adverse reactions between the control group and the observation group(P>0.05). Conclusion For patients with uterine atony-induced postpartum hemorrhage, combined treatment with ergometrine on the basis of oxytocin can not only effectively reduce the postpartum blood loss, but also improve the coagulation function, alleviate the body's stress response indicators, and has relatively good safety profile.